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Background: Little information is available about posthypoglycemic hyperglycemia (PHH) in
diabetic cats, and a causal link between hypoglycemia and subsequent hyperglycemia is not clear.
Fluctuations in blood glucose concentrations might only represent high glycemic variability.
Hypothesis: Insulin induces PHH in healthy cats, and PHH is associated with poorly regulated dia-
betes and increased glycemic variability in diabetic cats.
Animals: Six healthy cats, 133 diabetic cats.
Methods: Insulin (protamine-zinc and degludec; 0.1-0.3 IU/kg) administered to healthy cats. Blood
glucose curves were generated with portable glucose meter to determine the percentage of curves
with PHH. Data from insulin-treated diabetic cats with blood glucose curves showing hypoglyce-
mia included data of cats with and without PHH. Post-hypoglycemic hyperglycemia was defined as
blood glucose concentrations <4 mmol/L followed by blood glucose concentrations >15 mmol/L
within 12 hours. Glycemic variability was calculated as the standard deviation of the blood glucose
concentrations.
Results: In healthy cats, all insulin doses caused hypoglycemia but PHH was not observed;
glycemic variability did not differ between insulin preparations. Among diabetic cats with
hypoglycemia, 33 (25%) had PHH. Compared with cats without PHH, their daily insulin dose was
higher (1.0960.55 versus 0.6560.56 IU/kg; P< .001), serum fructosamine concentration was
higher (5656113 versus 4306112 mmol/L; P< .001), remission was less frequent (10% versus
56%; P< .001), and glycemic variability was larger (8.162.4 mmol/L versus 2.962.2 mmol/L;
P< .001).
Conclusions and Clinical Importance: Insulin-induced hypoglycemia did not cause PHH in healthy
cats but it occurred in 25% of diabetic cats with hypoglycemia, particularly when diabetes was
poorly controlled. Glycemic variability was increased in cats with PHH.
K E YWORD S
cat, diabetes mellitus, endocrinology, pancreas
Abbreviations: DM, diabetes mellitus; ID, insulin degludec; PHH, posthypoglycemic hyperglycemia; PZI, protaminezinc insulin; SD, standard deviation.
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1 | INTRODUCTION
It has been postulated that hypoglycemia induced by a slight overdose
of insulin leads to counter-regulatory hormone release and subsequent
hyperglycemia in humans with diabetes mellitus (DM). This phenom-
enon, also known as rebound hyperglycemia or the Somogyi effect,
was characterized by nocturnal hypoglycemia followed by early morn-
ing fasting hyperglycemia.1 Recent studies in human medicine have
cast doubt on the existence of rebound hyperglycemia as described by
Somogyi, or proposed that it is rare.2–4 Indeed, most humans with type
1 DM had fasting hypoglycemia and not hyperglycemia after nocturnal
hypoglycemia.2,3 Furthermore, diabetic patients with the phenomenon
did not have higher concentrations of counter-regulatory hormones
than diabetics without it, but had a relative insulin deficiency, suggest-
ing that increased fasting blood glucose is related to insufficient insulin
treatment.4
In human diabetology, the concept of glycemic variability has
gained particular attention in recent years.5,6 Although currently there
is no uniformly accepted definition, glycemic variability refers to
intraday glycemic excursions consisting of episodes of hypoglycemia
followed by hyperglycemia, or of hyperglycemia followed by hypogly-
cemia, with no apparent causal link.6 Hence, the main differences
between the definitions of rebound hyperglycemia and glycemic vari-
ability are timing and sequence; rebound hyperglycemia is nocturnal to
early morning hypoglycemia followed by hyperglycemia, whereas glyce-
mic variability refers to oscillations of blood glucose concentrations
including episodes of hypoglycemia and hyperglycemia that occur
during the day or night.
In cats, information pertaining to blood glucose concentrations
after insulin-induced hypoglycemia is scarce and its clinical relevance is
currently unknown.7,8 To date, only the term rebound hyperglycemia
has been used in diabetic cats,7,8 and the event was described during
the day, in contrast to the Somogyi’s classical definition described in
human diabetics which occurs at night. In the first description of
rebound hyperglycemia in 6 diabetic cats,7 cats were receiving a single
daily insulin dose of 2–22 IU/cat at the time of rebound hyperglycemia,
and in 4 of them the phenomenon did not recur after the dose of insu-
lin was decreased or the type of insulin was changed.7 In 2016, a sec-
ond investigation based on data provided by owners in a web-based
forum described rebound hyperglycemia in 14 of 55 (25.5%) insulin-
treated diabetic cats.8 Overall, however, only 45 of 10 767 (0.4%)
blood glucose curves showed rebound hyperglycemia. No association
was found between the episodes and the amount of insulin adminis-
tered.8 In contrast to rebound hyperglycemia, the concept of glycemic
variability has not yet been investigated.
In our study, the more generic term posthypoglycemic hyperglyce-
mia (PHH) is proposed in cats instead of rebound hyperglycemia
because a causal link between low and subsequent high glucose con-
centrations is uncertain. Our aims were to determine whether PHH
occurs after insulin-induced hypoglycemia in healthy cats and to define
the frequency of PHH in diabetic cats. Moreover, signalment, insulin
treatment, clinicopathologic data, metabolic control, and remission
were evaluated and compared in diabetic cats with and without PHH.
Glycemic variability also was explored in healthy and in diabetic cats.
2 | MATERIALS AND METHODS
2.1 | Healthy cats and insulin treatment
Six, healthy, purpose-bred, neutered male, domestic shorthair cats, with
a mean age of 3.760.1 years and a mean body weight of 5.060.2 kg
were treated with protamine zinc insulin (PZI; ProZinc, Boehringer
Ingelheim, Ingelheim am Rhein, Germany) and insulin degludec (ID;
Tresiba, Novo Nordisk Pharma, Bagsværd, Denmark), as previously
reported.9 The cats were housed in the animal research facility of the
Vetsuisse Faculty, University of Zurich, and were fed a commercial dry
food (Feline Adult Light, Hill’s Pet Nutrition, Topeka, Kansas), twice
daily. Cats had continuous access to water, and food intake was
adjusted to maintain stable body weight. The cats were housed in indi-
vidual standard hospital cages for 24 hours before and 24 hours after
insulin administration. Food was withheld for 10 hours before and 24
hours after insulin administration. The 2 insulin preparations and their
dosages were tested in a randomized crossover trial. Each cat received
0.1, 0.2, and 0.3 IU/kg of PZI or ID SC, 2 weeks apart. The dose was
rounded up to the nearest half unit. Capillary blood for blood glucose
determination using a portable blood glucose meter (AlphaTRAK2;
Abbott Animal Health, Abbott Park, Illinois) was collected from the
inner pinna 30 and 5 minutes before, and 30, 60, 90, 120, 180, 240,
300, and 360 minutes after insulin injection, and every 2 hours during
the following 18 hours. Hypoglycemia was arbitrarily defined as blood
glucose concentration <4 mmol/L and PHH as blood glucose concen-
tration <4 mmol/L followed by an increase in blood glucose concentra-
tion >15 mmol/L within 12 hours of the administration of insulin.
When hypoglycemia caused tremors, vocalization, vomiting, or
seizures, an additional meal was offered or 50% glucose solution was
administered IV, and the cat was withdrawn from the study. When a
decrease in physical activity was the only clinical sign observed, no
attempt was made to correct the hypoglycemia. The study protocol
was approved by the Cantonal Veterinary Office of Zurich (permission
number: 110/2014).
2.2 | Diabetic cats and insulin-induced hypoglycemia
The medical records of the Clinic for Small Animal Medicine of the Vet-
suisse Faculty, University of Zurich, were searched for diabetic cats
admitted between 1997 and 2014. Cats were included in the study
provided they were receiving insulin treatment and at least 1 blood glu-
cose curve, generated at our clinic or at home by the owner, was avail-
able. It was necessary that blood glucose curves include at least 4
measurements over a 12-hours period and show hypoglycemia; cats
with curves generated over a longer period were excluded. The blood
glucose curves were evaluated for nadir, time to nadir, and episodes of
PHH. The definitions of hypoglycemia and PHH were the same as
those used in healthy cats. The signalment, including age, body weight,
sex (male, female, neutered), and breed (crossbred, purebred), type of
2 | Journal of Veterinary Internal Medicine ZINI ET AL.
insulin (glargine [Lantus, Sanofi Aventis, Meyrin, Switzerland] or porcine
zinc [Caninsulin, MSD Animal Health, Luzern, Switzerland]), daily insulin
dose, quality of metabolic control, occurrence of diabetic remission,
and serum fructosamine concentration at the time of hypoglycemia
were retrieved from the medical records. The quality of metabolic con-
trol was defined as good when cats on insulin treatment had no clinical
signs of DM (eg, polyuria, polydipsia, polyphagia), body weight was sta-
ble, and serum fructosamine concentration was only slightly increased
(350–450 mmol/L; reference interval, 200–340 mmol/L). The occur-
rence of diabetic remission was defined as the absence of clinical signs
of DM and normal blood glucose and fructosamine concentrations for
at least 4 weeks after discontinuation of insulin treatment.10 The
chance of remission is highest during the first 6 months after diagnosis
of DM,10 and thus a follow-up examination at a minimum of 6 months
after the start of insulin treatment was considered necessary. Cats that
required insulin treatment but had had their last follow-up examination
<6 months after initial presentation were excluded for analysis of
remission.
2.3 | Statistical analysis
Commercial software (GraphPad Prism version 5.0, GraphPad Soft-
ware, La Jolla, California) was used for all calculations. In healthy cats,
the frequencies of hypoglycemia and PHH were calculated for both
insulin preparations. The percentages of blood glucose curves with at
least 1 blood glucose concentration above baseline after the hypogly-
cemic episode were computed. For each cat, blood glucose concentra-
tions after hypoglycemia were considered to be significantly higher
than baseline when they were greater than the mean of the blood
glucose concentrations recorded 30 and 5 minutes before insulin
administration plus the 90% range of differences. The 90% range of
differences was calculated using previously described method.11 In
brief, all blood glucose concentrations recorded at 30 and 5 minutes
before insulin administration were used to calculate the critical value of
the t-distribution and the residual mean square from analysis of variance;
the formula of the 90% range of differences was: ðcritical valueÞ3
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃððresidualmean squareÞ=21ðresidualmean squareÞÞp .11
In diabetic cats, the frequency of PHH was calculated only for
those with documented hypoglycemia. Differences between cats with
and without PHH with respect to sex, breed, insulin type, location
where the blood glucose curve was generated, rate of good metabolic
control, and remission were analyzed using a chi-square test, and dif-
ferences with respect to age, body weight, daily insulin dose, serum
fructosamine concentrations, nadir, and time to nadir of blood glucose
curves with hypoglycemia were analyzed using a t-test. Data were
tested for normal distribution using the Shapiro-Wilk test, and non-
normal data were log-transformed and then analyzed using parametric
tests. The Bonferroni correction was applied to account for multiple
comparisons and adjusted P-values were calculated. Data were
reported as means6 standard deviations (SD) or as percentages.
The SD describes the dispersion of data on both sides of the mean
and is considered the simplest approach for the evaluation of glucose
variability in human diabetics.12 Hence, the SD was calculated from
blood glucose concentrations from the blood glucose curve in each dia-
betic cat with and without PHH, and in each healthy cat. In human
medicine, glycemic variability is considered acceptable when the SD of
the blood glucose curve does not exceed mean/2 for patients with
type 1 DM and mean/3 for patients with type 2 DM.12 The percen-
tages of cats with acceptable glycemic variability based on these 2 for-
mulas were calculated. The difference between the SDs of all cats with
PHH and of all cats without PHH was analyzed using a t-test with
Levene’s test to assess equality of variances. This analysis was
performed to verify whether cases with PHH had greater glycemic
variability than those without PHH. Fisher’s exact test was used for
comparison of the percentages of cats with and without PHH with
acceptable glycemic variability. In cats with PHH having a second blood
glucose curve available, comparison of paired SDs and of percentages
of acceptable glycemic variability between curves were carried out
using the Wilcoxon paired test and Fisher’s exact test, respectively.
Differences between SDs of healthy cats treated with PZI and those
treated with ID were examined for each dosage (0.1, 0.2, and
0.3 IU/kg) using the Wilcoxon paired test. Differences were considered
significant at P< .05.
3 | RESULTS
3.1 | Healthy cats and insulin treatment
In healthy cats, hypoglycemia was observed after all 36 (100%) insulin
administrations, regardless of the type of insulin used (Figure 1). At the
highest dosage (0.3 IU/kg), PZI and ID caused hypoglycemia (1.2 and
1.8 mmol/L, respectively), which was associated with an episode of
vomiting in 3 cats (2 with PZI, 1 with ID). Each of the 3 cats was
offered a meal, which resulted in prompt correction of the hypoglyce-
mia. The blood glucose curves of these 3 cats were excluded from all
analyses. In all other cases, administration of PZI and ID led to a
decrease in physical activity, which was associated with hypoglycemia
and resolved without treatment within 1–3 hours after insulin
administration.
None of the hypoglycemic episodes induced PHH. However, in 4
of 33 (12.1%) available blood glucose curves, blood glucose concentra-
tions after hypoglycemia slightly exceeded baseline; 3 cats had
received PZI at dosages of 0.1, 0.2, and 0.3 IU/kg, respectively, and 1
had received ID at a dosage of 0.2 IU/kg. The glucose values and dif-
ferences above baseline were 5.7 and 10.3 mmol/L, 4.9 and 10.3
mmol/L, and 5.8 and 10.1 mmol/L in cats given PZI and 5.6 and 10.3
mmol/L in the cat that received ID.
Results of glycemic variability in healthy cats treated with PZI and
ID are shown in Table 1. The SDs did not differ between PZI and ID at
any of the 3 dosages administered.
3.2 | Diabetic cats and insulin-induced hypoglycemia
The medical records of 300 diabetic cats with DM were retrieved and
yielded a total of 2106 blood glucose curves for evaluation. Blood glu-
cose curves with hypoglycemia were documented in 133 of the 300
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(44.3%) diabetic cats. Of those 133 diabetic cats, 33 (24.8%) had PHH
and 100 (75.2%) did not (Figure 2). Posthypoglycemic hyperglycemia
was identified in 11% of all diabetic cats and in 1.7% of all glucose
curves. With regard to blood glucose curves of the 133 diabetic cats,
the mean number of glucose measurements in each curve was 661
and the mean duration of each curve was 962 hours.
In the group of 33 cats with PHH, the mean age was 10.363.4
years and the mean body weight was 5.561.5 kg. Twenty-one cats
(63.6%) were neutered males and 12 (36.4%) were spayed females.
Twenty-four were domestic shorthair or longhair (72.7%) and 9 were
purebred (27.3%) cats. In the group of 100 cats without PHH, the mean
age was 11.363.2 years and the mean body weight was 5.461.4 kg;
age was unknown in 1 cat. Seventy-four cats (74%) were male, includ-
ing 72 neutered and 2 intact, and 26 (26%) were female, including 25
spayed and 1 intact cat. Seventy-six were domestic shorthair or longhair
(76%) and 24 were purebred (24%) cats. Cats with and without PHH
did not differ in age, body weight, sex, or breed distribution.
The proportions of cats treated with insulin glargine and porcine-
zinc insulin did not differ between groups (P5 .205) and comprised
42.4% and 57.6% of the group with PHH and 64% and 36% of the
group without PHH, respectively. The daily amount of insulin adminis-
tered per kg in cats with PHH was significantly higher than in cats with-
out PHH (1.0960.55 versus 0.6560.56 IU/kg; P< .001; Figure 3).
Serum fructosamine concentrations were available for 15 cats with
PHH and 85 without PHH; serum fructosamine concentration was sig-
nificantly higher in the group with PHH (5656113 versus 4306112
mmol/L; P< .001; Figure 4). Good metabolic control was documented in
1 of 15 (6.7%) cats with PHH and in 58 of 85 (69.4%) in the group with-
out PHH; the prevalence of good metabolic control was significantly
lower in cats with PHH (P< .001). Glucose nadir (2.760.8 versus 2.86
0.7 mmol/L; P51.000) and time to nadir (4.061.6 versus 4.962.5
hours; P5 .530) did not differ in diabetic cats with and without PHH.
Finally, the frequency of blood glucose curves generated at home and
at the hospital was 48.5% and 51.5% in cats with PHH versus 13% and
87% in cats without PHH; blood glucose curves generated at home
were significantly more common in the PHH group (P< .001).
With regard to glycemic variability, the SDs were significantly
higher in cats with PHH than in cats without PHH (8.162.4 mmol/L
versus 2.962.2 mmol/L; P< .001). Using the formulas for evaluation
of the rate of acceptable glycemic variability in humans with type 1 and
2 DM,11 3 (9.1%) and 0 (0%) cats with PHH and 63 (63%) and 40 (40%)
cats without PHH had acceptable glycemic variability. Based on the
FIGURE 1 Blood glucose curves showing hypoglycemia in healthy cats (2 cats treated with PZI and 1 treated with ID were excluded
because received a meal to correct hypoglycemia) treated with PZI at 0.1 (A), 0.2 (B), and 0.3 IU/kg (C) or ID at 0.1 (D), 0.2 (E), and
0.3 IU/kg (F). Median and range are shown for each time point
TABLE 1 Assessment of glycemic variability based on calculation of
the SD of the blood glucose curve in healthy cats treated with PZI
versus ID at each dosage (0.1, 0.2, and 0.3 IU/kg)
Insulin (type and
dosage)
Glycemic variabilitya
(mean6 SD; mmol/L) P value
PZI 0.1 IU/kg 1.06 0.4 .589
ID 0.1 IU/kg 1.16 0.5
PZI 0.2 IU/kg 1.26 0.2 .589
ID 0.2 IU/kg 1.16 0.5
PZI 0.3 IU/kg 1.26 0.2 .905
ID 0.3 IU/kg 1.26 0.2
PZI total 1.16 0.3 .986
ID total 1.16 0.4
Abbreviation: SD, standard deviation.
Note that SD refers only to the SD of the mean of the SDs of the glu-
cose curves (ie, those used to assess glycemic variability).
aTwo cats treated with PZI and 1 treated with ID were excluded because
received a meal to correct hypoglycemia.
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values for both criteria, cats with PHH were significantly less likely to
have acceptable glycemic variability than those without PHH (P< .001
for each comparison).
3.3 | Follow-up of diabetic cats
Overall, 47 cats (43.1%) had remission from DM and 62 (56.9%) did
not. Twenty-four cats that required insulin treatment, consisting of
3 in the group with PHH and 21 in the group without PHH, had their
final follow-up examination <6 months after initial presentation and
were excluded from analysis. Remission was achieved in 3 of the 30
cats (10%) with PHH and in 44 of the 79 cats (55.7%) without PPH;
the rate of remission was significantly lower in cats with PHH
(P< .001).
Of the 33 cats with PHH, 31 (93.4%) had a blood glucose curve
repeated an average of 14615 days after the curve showing PHH. A
second episode of PHH occurred in 2 of the 31 (6.5%) cats and in both
cases the dose of insulin had not been decreased after the first episode
of PHH. A second episode of PHH was not documented in the remain-
ing 29 cats; the dose of insulin had been decreased by an average of
37618% in 12, not been changed in 11 (37.9%), and increased in the
remaining 6 (20.7%). The complete clinical and clinicopathologic data
used by the attending veterinarian to increase or maintain the amount
of insulin prescribed were not available from the medical records.
Regarding glycemic variability of the 31 blood glucose curves, their
SDs were 4.863.1 mmol/L. Compared with initial curves with PHH,
the SD calculated in a repeated blood glucose curve was significantly
lower (P< .001); SD decreased in 26 of 31 (83.9%) curves. Using the
formulas for humans with type 1 and 2 DM,12 24 (77.4%) and
19 (61.3%) of 31 blood glucose curves had acceptable glycemic
variability. Compared with initial curves with PHH, the frequency of
acceptable glycemic variability was significantly increased using either
formula (P< .001, for each).
4 | DISCUSSION
Administration of PZI and ID at all dosages in healthy cats resulted in
hypoglycemia but was not associated with PHH. It appears that even
after episodes of severe hypoglycemia, healthy cats are able to fine-
tune glycemia so that the secretion of counter-regulatory hormones,
released in response to hypoglycemia, is transient and quickly offset
once normoglycemia is restored. Hence, PHH did not occur in this
population of healthy cats. Epinephrine and corticosteroids are
FIGURE 2 Scatter plots of blood glucose curves in diabetic cats with posthypoglycemic hyperglycemia (A) and without PHH (B). The gray
box depicts the glucose concentrations between 4 and 15 mmol/L. Means are shown as horizontal bars in each scatter plot
FIGURE 3 Scatter plots of daily insulin dose in diabetic cats with
PHH and without PHH. Means are shown as horizontal bars in
each scatter plot
FIGURE 4 Scatter plots of serum fructosamine concentrations in
diabetic cats with PHH and without PHH. Means are shown as
horizontal bars in each scatter plot
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counter-regulatory hormones that have been shown to play an impor-
tant role in glycemic control in cats with hypoglycemia. In 1 study
healthy cats that received 10 IU/kg of insulin had a 10-fold increase in
circulating epinephrine with the highest concentration recorded during
the glucose nadir; epinephrine secretion ceased with IV administration
of a glucose solution.13 In another study, healthy cats that received
4 IU/kg of insulin had a 6-fold increase in circulating corticosteroids
within 1 hour of administration.14 However, neither of the studies
reported whether hyperglycemia occurred after insulin-induced hypo-
glycemia. Only 12% of the blood glucose curves of healthy cats had
measurements slightly above baseline after insulin-induced hypoglyce-
mia (ranging from10.1 to10.3 mmol/L), which probably reflected nor-
mal physiological variability. Therefore, insulin administration in healthy
cats causes hypoglycemia, but compensatory mechanisms appear to
prevent blood glucose concentrations from exceeding baseline and
resulting in hyperglycemia. The dosage of insulin administered to
healthy cats in our study was much lower than that used in previous
studies,13,14 and it is not known whether higher doses of insulin would
have caused more marked hypoglycemia followed by a more
pronounced increase in blood glucose concentration. Furthermore, lack
of counter-regulatory hormone measurement also precludes further
conclusions with respect to our findings.
Assessment of glycemic variability showed no differences between
healthy cats treated with PZI and those treated with ID, at any of the 3
dosages. Therefore, the 2 insulin preparations seem to cause similar
fluctuations in blood glucose concentrations when administered to
healthy cats. Further studies are needed to clarify the usefulness of SD
for assessment of glycemic variability in experiments using different
insulin preparations in healthy cats.
Of the 300 diabetic cats with complete medical records, almost
half had a blood glucose curve showing hypoglycemia, and 25% of
these had PHH. Of all diabetic cats, approximately 10% had PHH,
which shows that this phenomenon is common and in agreement with
a recent investigation describing PHH in 25% of diabetic cats.8
Although PHH occurred in a considerable number of diabetic cats, the
proportion of blood glucose curves with PHH was low at 1 in 50 in
our investigation and 1 in 200 in a previous study.8 Therefore, although
some diabetic cats may have blood glucose curves with PHH, this phe-
nomenon may be observed only once. In our study, only 6.5% of dia-
betic cats with PHH had a second episode of PHH, whereas most did
not. A continuous glucose monitoring system rather than a portable
blood glucose meter may have been a better tool to evaluate the
occurrence of PHH.
Although episodes of PHH were seen only once in the majority of
diabetic cats, there were several intriguing features associated with this
phenomenon. For example, diabetic cats with PHH received almost
twice as much daily insulin per kg as did diabetic cats without PHH and
had 25% higher serum fructosamine concentrations. Furthermore,
good metabolic control was seen in 70% of cats without PHH, but in
only 6.7% of cats with PHH. At first glance, these results may merely
suggest that DM is more difficult to treat in cats with PHH than in cats
without PHH. Alternatively, the data would support the hypothesis
that an excessively high dosage of insulin leads to PHH, which in turn
renders the management of DM more difficult in cats, as originally
assumed in diabetic humans presented with rebound hyperglycemia or
the Somogyi effect.1 However, the existence of this phenomenon has
been questioned, and in the majority of human diabetics the episodes
were shown to be attributable to short duration of insulin action rather
than rebound hyperglycemia.2–4 Unfortunately, it was not possible to
assess the duration of insulin action from the blood glucose curves and
therefore determine whether the effect of insulin was shorter in cats
with PHH. Blood glucose curves spanning >12 hours would have been
necessary to make this determination. Time to nadir did not differ
between cats with and without PHH,15 but this parameter does not
necessarily mirror the duration of insulin action. In addition, no differ-
ences were observed between the nadir, which suggests that hypogly-
cemia was not more severe in cats with PHH, although they had
received more insulin than did diabetic cats without PHH. Epinephrine
secretion is a variable that appears to reflect the degree of hypoglyce-
mia in cats,14 and thus it is possible that PHH occurs when there is
marked hypoglycemia. Why PHH occurs in some diabetic cats but not
in others, despite a similar degree of hypoglycemia, remains unclear.
By calculating the SD of glucose concentrations in blood glucose
curves, cats with PHH had higher glycemic variability than did those
without PHH. The importance of decreasing large excursions in glucose
concentrations to improve glycemic variability recently was highlighted
in human medicine, and is considered by some authors to be as crucial
as decreasing glycated hemoglobin.16 The rationale behind calculation
of glycemic variability is that optimal values of glycated hemoglobin in
some diabetic patients do not rule out the presence of relevant fluctua-
tions in blood glucose concentrations, such as phases of marked hypo-
glycemia and hyperglycemia, which necessitate prompt treatment.16 In
addition, glycemic variability was shown to be associated with the
development of diabetic retinopathy in humans with type 1 and 2 DM,
and higher glycemic variability was observed in patients with this ocular
complication, regardless of glycated hemoglobin results.17 Based on
our experience, fluctuations are frequently observed in blood glucose
curves in cats with DM. Therefore, the concept of glycemic variability
relative to PHH was investigated in this species using the SD, which is
the simplest formula available in human medicine.12 Further studies are
needed to determine whether higher glycemic variability plays a role in
the occurrence of diabetic complications, such as polyneuropathy and
ketoacidosis, or in remission and survival. Of note, glycemic variability
was less likely to be acceptable in cats with PHH (10%) than in cats
without PHH (50%). Although these results may not look promising,
it is worth noting that the initial application of glycemic variability,
which has so far not been optimized for cats, proved useful and
showed clear differences in a population of diabetic cats with hypogly-
cemia. Actually, it is possible that selection bias was introduced by
including only diabetic cats with episodes of hypoglycemia. The general
population of diabetic cats, including those with and without hypogly-
cemia, might have a higher rate of acceptable glycemic variability than
this group.
Follow-up examinations in diabetic cats showed that remission
occurred in only 10% of those with PHH compared with almost 66%
of those without PHH. Our finding suggests that when a blood glucose
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curve shows PHH, every effort should be made to improve the chance
of remission. Although our results showed that PHH was seen only
once in most cats with DM, it is probable that metabolic control in dia-
betic cats remains inadequate over time and eventually decreases the
viability of pancreatic b-cells, making remission unlikely. It is unclear if
glycemic variability decreases the chances of remission in cats. Our
investigation showed that cats with PHH had follow-up blood glucose
curves with improved SD and rate of acceptable glycemic variability.
Therefore, glycemic variability may play only a limited role in remission.
However, to elucidate the relevance of glycemic variability longitudinal
studies with several blood glucose curves are definitely required.
Of note, after the episode of PHH, the attending veterinarian in
approximately half of the cases did not decrease the dose of insulin.
Despite this, PHH was not demonstrated in the subsequent blood glu-
cose curves in most of these cats. This surprising finding might be
explained by the fact that some inconsistency of blood glucose curves
has been demonstrated in diabetic cats, in particular if DM is poorly
controlled, even if curves are repeated on the subsequent day and
insulin dose, amount of food, and type of food are left unchanged.18
Information regarding diets was not available. Therefore, it is possible
that dietary changes also contributed to blood glucose concentrations
in the follow-up curves.
Finally, blood glucose curves more often were generated at home
than in the hospital in cats with PHH compared to cats without PHH.
The hospital setting is expected to be associated with more stress,
which would decrease the overall chance of hypoglycemia and, pre-
sumably, of PHH. Furthermore, cats with an episode of hypoglycemia
in the hospital may be unwilling to eat because of environmental stress,
thus preventing subsequent hyperglycemia. However, owners at home
may easily increase blood glucose concentrations of their cats by offer-
ing an additional meal in case of hypoglycemia, favoring PHH. Because
of the retrospective nature of our study, information regarding feeding
was insufficient both for cats with hospital and home-based glucose
curves to make any assumption on the role of diet on PHH.
Using the results of blood glucose curves generated with portable
glucose meters rather than with continuous glucose monitoring sys-
tems represents a potential limitation of our study. True nadirs and
fluctuations in glucose concentrations of short duration can be missed
when using portable blood glucose meters.19 However, the potential
bias caused by the use of portable glucose meters instead of
continuous glucose monitoring systems was likely minor because porta-
ble glucose meters were used consistently in all of the cats. Further-
more, it is worth reiterating that the results of our study on diabetic
cats come from a selected population of cases with hypoglycemia, and
interpretation of data cannot be extended to the general population of
diabetic cats.
In conclusion, insulin-induced hypoglycemia did not cause PHH in
our population of healthy cats, although posthypoglycemia blood
glucose concentrations slightly exceeded baseline in some cats.
Furthermore, glycemic variability was similar in cats treated with PZI
and ID. Posthypoglycemic hyperglycemia occurred in approximately
25% of diabetic cats with hypoglycemia and was associated with higher
insulin doses, higher serum fructosamine concentrations, worse
metabolic control, lower risk of remission, and increased glycemic vari-
ability compared with diabetic cats without PHH. The reason why PHH
is only seen in certain diabetic cats and not others currently is unclear.
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